Faizi Hai, MD
Gastroenterology · San Diego, CANPI 1639523228
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 203 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by AbbVie at 43.6% of the total. Reporting peaked in 2022 at $2,267 and has fallen 54.3% since, to $1,036 in 2025.
Across 203 payments — averaging $32.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Takeda Pharmaceuticals U.S.A., Inc.$832
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$622
- Sanofi$363
- Regeneron Healthcare Solutions, Inc.$323
- Johnson & Johnson$276
- plus $1K from 19 others
What the payments were for
- Food & beverage$6,696100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 70 | $2,920 |
| Takeda Pharmaceuticals U.S.A., Inc. | 31 | $832 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 27 | $622 |
| Sanofi | 10 | $363 |
| Regeneron Healthcare Solutions, Inc. | 9 | $323 |
| Johnson & Johnson | 15 | $276 |
| Intercept Pharmaceuticals, Inc. | 5 | $204 |
| Madrigal Pharmaceuticals | 1 | $134 |
| Aimmune Therapeutics, Inc. | 1 | $125 |
| Mallinckrodt Hospital Products Inc. | 1 | $119 |
| Merck | 6 | $118 |
| Boston Scientific | 1 | $115 |
| Pfizer | 5 | $100 |
| QOL Medical, LLC | 3 | $72 |
| Gilead | 1 | $71 |
| Phathom Pharmaceuticals, Inc. | 4 | $68 |
| Bristol Myers Squibb | 3 | $46 |
| Vivus LLC | 2 | $39 |
| Braintree Laboratories, Inc. | 2 | $27 |
| Alnylam Pharmaceuticals Inc. | 1 | $26 |
| Novo Nordisk | 1 | $23 |
| Ferring Pharmaceuticals Inc. | 1 | $22 |
| Blueprint Medicines Corporation | 1 | $22 |
| GSK | 1 | $15 |
| Olympus America Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,696 in reported general payments places this provider in the 70th percentile of 1,885 gastroenterology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other gastroenterology in San Diego
- William SandbornSan Diego$340K
- David KunkelSan Diego$287K
- Naveen GaraSan Diego$178K
- Bennett RothLos Angeles$2.8M
- Douglas NguyenMission Viejo$2M
- Sammy SaabLos Angeles$1.9M
- Kenneth ChangNewport Beach$1.3M
- Joo HwangStanford$1M
- Drew SchembreWalnut Creek$659K
- Quan Nhula Jolla$641K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.